Gilead Sciences has shored up its position in cell therapies for cancer with a deal to acquire Arcellx, a company it has been ...
CagriSema was submitted for FDA approval last December as a treatment for obesity last December, with a decision due later ...
Among the issues highlighted by patients in the study were lengthy waits for appointments, obstacles to changing or ...
On the sidelines of JPM, Daiichi-Sankyo US CEO Ken Keller told pharmaphorum about the company's big year and its long-term s ...
As reported in January this year, the United States Centers for Medicare & Medicaid Services (CMS) rolled out $10 billion in rural health funding to states in what was the first distribution of ...
Many of the UK’s most promising life sciences innovations continue to face persistent funding challenges, made worse by an increasingly volatile global trade environment. Without sustained investment, ...
The combination of AstraZeneca's Calquence and AbbVie/Roche's Venclexta has become the first all-oral, fixed-duration regimen for patients with newly-diagnosed chronic lymphocytic leukaemia (CLL) in ...
The imposition of new levies evaporated any hope that SCOTUS' decision would give some respite from the relentless disruption resulting from Trump's 'Liberation Day' tariffs, which were imposed in ...
Earlier this week, NHS England said that production problems at German company Heraeus Medical – which is the main supplier ...
The FDA plans to adopt a new policy that will do away with the default requirement to base regulatory filings for new ...
The agreement gives MSD (known as Merck & Co in the US and Canada) access to the Mayo Clinic Platform architecture – which ...
Traditional virtual engagement often forces patients into a corporate mould – a 60-minute, high-pressure web meeting where ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results